Form 8-K - Current report:
SEC Accession No. 0001193125-25-308769
Filing Date
2025-12-05
Accepted
2025-12-05 08:58:00
Documents
10
Period of Report
2025-12-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20251201.htm   iXBRL 8-K 56579
  Complete submission text file 0001193125-25-308769.txt   168781

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20251201.xsd EX-101.SCH 28463
12 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20251201_htm.xml XML 4711
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 251551323
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)